CL2013003646A1 - Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros. - Google Patents

Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros.

Info

Publication number
CL2013003646A1
CL2013003646A1 CL2013003646A CL2013003646A CL2013003646A1 CL 2013003646 A1 CL2013003646 A1 CL 2013003646A1 CL 2013003646 A CL2013003646 A CL 2013003646A CL 2013003646 A CL2013003646 A CL 2013003646A CL 2013003646 A1 CL2013003646 A1 CL 2013003646A1
Authority
CL
Chile
Prior art keywords
psychosis
treatment
pharmaceutical composition
phenylindan
trimethylpiperazine
Prior art date
Application number
CL2013003646A
Other languages
English (en)
Spanish (es)
Inventor
Morten Jorgensen
Peter Hongaard Andersen
Mette Graulund Hvenegaard
Klaus Gjervig Jensen
Mikkel Fog Jacobsen
Lassina Badolo
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2013003646A1 publication Critical patent/CL2013003646A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CL2013003646A 2011-06-20 2013-12-19 Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros. CL2013003646A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498651P 2011-06-20 2011-06-20
US201161537103P 2011-09-21 2011-09-21

Publications (1)

Publication Number Publication Date
CL2013003646A1 true CL2013003646A1 (es) 2014-07-04

Family

ID=46682855

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003646A CL2013003646A1 (es) 2011-06-20 2013-12-19 Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros.

Country Status (40)

Country Link
US (9) US8575174B2 (https=)
EP (4) EP3508468B1 (https=)
JP (1) JP5668177B2 (https=)
KR (2) KR101879474B1 (https=)
CN (1) CN103649019B (https=)
AP (1) AP3310A (https=)
AR (1) AR086987A1 (https=)
AU (1) AU2012273657B2 (https=)
BR (1) BR112013031702B1 (https=)
CA (1) CA2837820C (https=)
CL (1) CL2013003646A1 (https=)
CO (1) CO6821965A2 (https=)
CR (1) CR20130654A (https=)
CY (2) CY1118158T1 (https=)
DK (2) DK2720989T3 (https=)
DO (1) DOP2013000305A (https=)
EA (1) EA024651B1 (https=)
EC (1) ECSP14013155A (https=)
ES (3) ES2601213T3 (https=)
GE (1) GEP201706655B (https=)
GT (1) GT201300304A (https=)
HR (2) HRP20161348T1 (https=)
HU (2) HUE044043T2 (https=)
IL (1) IL229640B (https=)
JO (1) JO3128B1 (https=)
LT (2) LT3135656T (https=)
MA (1) MA35268B1 (https=)
MD (1) MD4538C1 (https=)
ME (2) ME03375B (https=)
MX (1) MX339552B (https=)
MY (1) MY196998A (https=)
PE (2) PE20141113A1 (https=)
PH (1) PH12013502598A1 (https=)
PL (2) PL3135656T3 (https=)
PT (2) PT2720989T (https=)
RS (2) RS55304B1 (https=)
SI (2) SI2720989T1 (https=)
SM (2) SMT201900179T1 (https=)
TW (3) TWI627956B (https=)
WO (1) WO2012176066A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3135656T3 (pl) 2011-06-20 2019-07-31 H. Lundbeck A/S Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
PT3679018T (pt) 2017-09-07 2022-04-05 Otsuka Pharma Co Ltd Processo industrial de monoalquilação de um nitrogénio de piperidina em derivados de piperidina com alquilo deuterado
EP3873885A1 (en) * 2018-10-29 2021-09-08 H. Lundbeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
EP3891134A1 (en) 2018-12-03 2021-10-13 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
EP3897507A4 (en) * 2018-12-21 2022-09-14 Terran Biosciences, Inc. DEUTERED FORMS AND DERIVATIVES OF VOLINANSERIN
JP7455810B2 (ja) * 2019-03-13 2024-03-26 大塚製薬株式会社 二級アミンを含有する化合物のアミン部分に重水素低級アルキルを導入する方法
CN117164518A (zh) * 2022-05-26 2023-12-05 四川大学 一种制备氘代咪唑类化合物的方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
GB8427125D0 (en) 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
EP0216785B1 (en) 1984-12-04 1991-01-30 Sandoz Ag Indene analogs of mevalonolactone and derivatives thereof
DK286990D0 (da) 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) * 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
WO1999015524A1 (en) 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
RS53369B (sr) * 2003-08-18 2014-10-31 H.Lundbeck A/S Sukcinat i malonat soli trans-4-((1r,3s)-6-hloro-3- fenilindan-1-il)-1,2,2-trimetilpiperazin i njihova upotreba kao medikamenta
BRPI0413595B8 (pt) 2003-08-18 2021-05-25 H Lundbeck As sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto
JP2008501749A (ja) 2004-06-08 2008-01-24 ニューロサーチ スウェーデン アクチボラゲット ドーパミン及びセロトニン神経伝達のモジュレーターとしての新規なジ置換フェニルピペリジン
RU2366654C2 (ru) 2004-06-08 2009-09-10 ЭнЭсЭйБи, ФИЛИАЛ АФ НЕУРОСЕРЧ СВИДЕН АБ, СВЕРИЙЕ Новые дизамещенные фенилпиперидины/пиперазины в качестве модуляторов допаминовой нейротрансмиссии
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
US20080269248A1 (en) 2005-02-16 2008-10-30 H. Lundbeck A/S Tartrate and Malate Salts of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine
CA2616383C (en) 2005-07-29 2015-06-09 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
HUE027865T2 (en) 2005-12-01 2016-11-28 Auspex Pharmaceuticals Inc Substituted phenyl ethylamines with serotonergic and / or norepinephrine activity
JP4986462B2 (ja) 2006-01-27 2012-07-25 シャープ株式会社 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
WO2008086158A1 (en) 2007-01-04 2008-07-17 Smithkline Beecham Corporation Benzodihydroquinazoline as pi3 kinase inhibitors
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
JP2010524972A (ja) 2007-04-19 2010-07-22 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化したモルホリニル化合物
EP1997479A1 (en) 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
AR066972A1 (es) 2007-06-12 2009-09-23 Concert Pharmaceuticals Inc Derivados azapeptidicos
US20090062303A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched ziprasidone
EA018927B1 (ru) 2008-05-07 2013-11-29 Х. Лундбекк А/С Способ лечения когнитивного расстройства, ассоциированного с шизофренией
AU2009298264A1 (en) 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
US20120071554A1 (en) 2008-10-28 2012-03-22 Liu Julie F Deuterated 2-propylpentanoic acid compounds
US8778401B2 (en) 2008-10-28 2014-07-15 Agency For Science, Technology And Research Mesoporous material excipients for poorly aqueous soluble ingredients
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
TW201102370A (en) 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
US8557994B2 (en) 2009-07-27 2013-10-15 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US8658236B2 (en) * 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN102020522A (zh) * 2009-09-21 2011-04-20 陈松源 氘代药物的制备方法和应用
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
WO2011084846A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Quaternary ammonium salt prodrugs
EP2639216B1 (en) 2010-11-09 2018-07-11 Kaneka Corporation Halogenated indenones and method for producing optically active indanones or optically active indanols by using same
JP2014501771A (ja) 2011-01-07 2014-01-23 ハー・ルンドベック・アクチエゼルスカベット ４−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン−１−イル）−１，２，２−トリメチル−ピペラジンと１−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン，１−イル）−３，３−ジメチル−ピペラジンとを分割するための方法
WO2012137225A1 (en) 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
PL3135656T3 (pl) 2011-06-20 2019-07-31 H. Lundbeck A/S Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii
US9487500B2 (en) 2012-10-04 2016-11-08 Inhibikase Therapeutics, Inc. Compounds and compositions thereof
AR094054A1 (es) 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma

Also Published As

Publication number Publication date
DOP2013000305A (es) 2014-02-28
PL2720989T3 (pl) 2017-05-31
EA201490045A1 (ru) 2014-07-30
US20160068497A1 (en) 2016-03-10
MD20140004A2 (en) 2014-05-31
EP3508468A1 (en) 2019-07-10
JP5668177B2 (ja) 2015-02-12
PT3135656T (pt) 2019-05-03
TWI614234B (zh) 2018-02-11
TW201311248A (zh) 2013-03-16
US20250250244A1 (en) 2025-08-07
CY1121514T1 (el) 2020-05-29
CR20130654A (es) 2014-03-24
JP2014520140A (ja) 2014-08-21
EP3135656A1 (en) 2017-03-01
US20220119362A1 (en) 2022-04-21
US20190031631A1 (en) 2019-01-31
KR101879474B1 (ko) 2018-07-17
BR112013031702A2 (pt) 2016-12-13
CN103649019A (zh) 2014-03-19
KR20180075717A (ko) 2018-07-04
AP2013007338A0 (en) 2013-12-31
SI3135656T1 (sl) 2019-05-31
HRP20161348T1 (hr) 2016-12-02
CO6821965A2 (es) 2013-12-31
US12116355B2 (en) 2024-10-15
SI2720989T1 (sl) 2016-11-30
MX339552B (es) 2016-05-31
US10501427B2 (en) 2019-12-10
NZ618222A (en) 2015-03-27
US20200131143A1 (en) 2020-04-30
IL229640A0 (en) 2014-01-30
LT2720989T (lt) 2016-11-25
ECSP14013155A (es) 2014-02-28
US11059798B2 (en) 2021-07-13
HUE044043T2 (hu) 2019-09-30
KR20140041567A (ko) 2014-04-04
EP3508468B1 (en) 2023-01-18
MX2013014849A (es) 2014-03-31
EP2720989A1 (en) 2014-04-23
EP3135656B1 (en) 2019-02-27
TWI627956B (zh) 2018-07-01
DK3135656T3 (en) 2019-04-23
AR086987A1 (es) 2014-02-05
US20170158650A1 (en) 2017-06-08
SMT201900179T1 (it) 2019-05-10
TW201722895A (zh) 2017-07-01
JO3128B1 (ar) 2017-09-20
WO2012176066A1 (en) 2012-12-27
RS58546B1 (sr) 2019-05-31
BR112013031702B1 (pt) 2021-11-03
ME03375B (me) 2020-01-20
PT2720989T (pt) 2016-11-07
US9617231B2 (en) 2017-04-11
DK2720989T3 (en) 2016-11-28
US20120322811A1 (en) 2012-12-20
MD4538C1 (ro) 2018-07-31
CY1118158T1 (el) 2017-06-28
TW201902481A (zh) 2019-01-16
CN103649019B (zh) 2015-09-16
US8575174B2 (en) 2013-11-05
ME02513B (me) 2017-02-20
CA2837820C (en) 2019-02-19
TWI659741B (zh) 2019-05-21
MD4538B1 (ro) 2017-12-31
HRP20190593T1 (hr) 2019-05-17
US9216961B2 (en) 2015-12-22
MY196998A (en) 2023-05-17
IL229640B (en) 2018-02-28
US10118907B2 (en) 2018-11-06
EP4215512A1 (en) 2023-07-26
HK1197228A1 (zh) 2015-01-09
PL3135656T3 (pl) 2019-07-31
RS55304B1 (sr) 2017-03-31
US9012453B2 (en) 2015-04-21
EA024651B1 (ru) 2016-10-31
GEP201706655B (en) 2017-04-25
US20130281436A1 (en) 2013-10-24
KR101939546B1 (ko) 2019-01-16
HUE030883T2 (en) 2017-06-28
MA35268B1 (fr) 2014-07-03
AU2012273657B2 (en) 2016-07-21
PE20150928A1 (es) 2015-06-26
GT201300304A (es) 2015-01-16
AU2012273657A1 (en) 2013-12-12
PH12013502598A1 (en) 2014-02-10
CA2837820A1 (en) 2012-12-27
SMT201600383B (it) 2017-01-10
LT3135656T (lt) 2019-04-25
AP3310A (en) 2015-06-30
ES2939477T3 (es) 2023-04-24
EP2720989B1 (en) 2016-08-10
ES2601213T3 (es) 2017-02-14
US20150307458A1 (en) 2015-10-29
ES2719145T3 (es) 2019-07-08
PE20141113A1 (es) 2014-09-25

Similar Documents

Publication Publication Date Title
CL2013003646A1 (es) Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros.
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
DOP2012000151A (es) Nuevos compuestos triciclicos
DOP2012000243A (es) Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales
CU20170144A7 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores gamma ror
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
PE20142285A1 (es) Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
MX2014012374A (es) Compuestos organicos.
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
DOP2014000121A (es) Derivados de betulina
UY32574A (es) Antagonistas del receptor cxcr3
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria